Literature DB >> 23637411

Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets.

Katharina Lind1, Sarah J Richardson, Pia Leete, Noel G Morgan, Olle Korsgren, Malin Flodström-Tullberg.   

Abstract

Type III interferons (IFNs), also called lambda interferons (IFN-λ), comprise three isoforms, IFN-λ1 (interleukin-29 [IL-29]), IFN-λ2 (IL-28A), and IFN-λ3 (IL-28B). Only limited information is available on their expression and biological functions in humans. Type I and type II IFNs protect human pancreatic islets against coxsackievirus infection, and this is important since such viruses have been proposed to play a role in the development of human type 1 diabetes. Here we investigated whether type III IFN is expressed during infection of human islet cells with coxsackievirus and if type III IFN regulates permissiveness to such infections. We show that human islets respond to a coxsackievirus serotype B3 (CVB3) infection by inducing the expression of type III IFNs. We also demonstrate that islet endocrine cells from nondiabetic individuals express the type III IFN receptor subunits IFN-λR1 and IL-10R2. Pancreatic alpha cells express both receptor subunits, while pancreatic beta cells express only IL-10R2. Type III IFN stimulation elicited a biological response in human islets as indicated by the upregulated expression of antiviral genes as well as pattern recognition receptors. We also show that type III IFN significantly reduces CVB3 replication. Our studies reveal that type III IFNs are expressed during CVB3 infection and that the expression of the type III IFN receptor by the human pancreatic islet allows this group of IFNs to regulate the islets' permissiveness to infection. Our novel observations suggest that type III IFNs may regulate viral replication and thereby contribute to reduced tissue damage and promote islet cell survival during coxsackievirus infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23637411      PMCID: PMC3700265          DOI: 10.1128/JVI.03431-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  41 in total

1.  Virus interference. I. The interferon.

Authors:  A ISAACS; J LINDENMANN
Journal:  Proc R Soc Lond B Biol Sci       Date:  1957-09-12

2.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Authors:  Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly
Journal:  Nat Immunol       Date:  2002-12-16       Impact factor: 25.606

3.  RNase L and double-stranded RNA-dependent protein kinase exert complementary roles in islet cell defense during coxsackievirus infection.

Authors:  Malin Flodström-Tullberg; Monica Hultcrantz; Alexandr Stotland; Amy Maday; Devin Tsai; Cody Fine; Bryan Williams; Robert Silverman; Nora Sarvetnick
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

4.  Functional impairment and killing of human beta cells by enteroviruses: the capacity is shared by a wide range of serotypes, but the extent is a characteristic of individual virus strains.

Authors:  M Roivainen; P Ylipaasto; C Savolainen; J Galama; T Hovi; T Otonkoski
Journal:  Diabetologia       Date:  2002-04-06       Impact factor: 10.122

5.  Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation.

Authors:  Ulrika Johansson; Annika Olsson; Susanne Gabrielsson; Bo Nilsson; Olle Korsgren
Journal:  Biochem Biophys Res Commun       Date:  2003-08-29       Impact factor: 3.575

6.  Enterovirus infection in human pancreatic islet cells, islet tropism in vivo and receptor involvement in cultured islet beta cells.

Authors:  P Ylipaasto; K Klingel; A M Lindberg; T Otonkoski; R Kandolf; T Hovi; M Roivainen
Journal:  Diabetologia       Date:  2004-01-15       Impact factor: 10.122

7.  Diabetogenic potential of human pathogens uncovered in experimentally permissive beta-cells.

Authors:  Malin Flodström; Devin Tsai; Cody Fine; Amy Maday; Nora Sarvetnick
Journal:  Diabetes       Date:  2003-08       Impact factor: 9.461

8.  Enterovirus-induced gene expression profile is critical for human pancreatic islet destruction.

Authors:  P Ylipaasto; T Smura; P Gopalacharyulu; A Paananen; T Seppänen-Laakso; S Kaijalainen; H Ahlfors; O Korsgren; J R T Lakey; R Lahesmaa; L Piemonti; M Oresic; J Galama; M Roivainen
Journal:  Diabetologia       Date:  2012-09-16       Impact factor: 10.122

9.  Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry.

Authors:  M S Horwitz; L M Bradley; J Harbertson; T Krahl; J Lee; N Sarvetnick
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

10.  Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture.

Authors:  Masafumi Goto; Torsten M Eich; Marie Felldin; Aksel Foss; Ragnar Källen; Kaija Salmela; Annika Tibell; Gunnar Tufveson; Keisei Fujimori; Margareta Engkvist; Olle Korsgren
Journal:  Transplantation       Date:  2004-11-15       Impact factor: 4.939

View more
  26 in total

Review 1.  The impact of anti-inflammatory cytokines on the pancreatic β-cell.

Authors:  M A Russell; N G Morgan
Journal:  Islets       Date:  2014       Impact factor: 2.694

2.  Interferon-α mediates human beta cell HLA class I overexpression, endoplasmic reticulum stress and apoptosis, three hallmarks of early human type 1 diabetes.

Authors:  Laura Marroqui; Reinaldo S Dos Santos; Anne Op de Beeck; Alexandra Coomans de Brachène; Lorella Marselli; Piero Marchetti; Decio L Eizirik
Journal:  Diabetologia       Date:  2017-01-06       Impact factor: 10.122

Review 3.  Potential role of type I interferon in the pathogenic process leading to type 1 diabetes.

Authors:  Natasha Qaisar; Agata Jurczyk; Jennifer P Wang
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2018-04       Impact factor: 3.243

4.  A preclinical study on the efficacy and safety of a new vaccine against Coxsackievirus B1 reveals no risk for accelerated diabetes development in mouse models.

Authors:  Pär G Larsson; Tadepally Lakshmikanth; Olli H Laitinen; Renata Utorova; Stella Jacobson; Maarit Oikarinen; Erna Domsgen; Minni R L Koivunen; Pascal Chaux; Nicolas Devard; Valerie Lecouturier; Jeffrey Almond; Mikael Knip; Heikki Hyöty; Malin Flodström-Tullberg
Journal:  Diabetologia       Date:  2014-11-05       Impact factor: 10.122

5.  Characterization of resident lymphocytes in human pancreatic islets.

Authors:  M Radenkovic; K Uvebrant; O Skog; L Sarmiento; J Avartsson; P Storm; P Vickman; P-A Bertilsson; M Fex; O Korgsgren; C M Cilio
Journal:  Clin Exp Immunol       Date:  2016-12-12       Impact factor: 4.330

Review 6.  Effects of type 1 diabetes-associated IFIH1 polymorphisms on MDA5 function and expression.

Authors:  Benjamin M Looney; Chang-Qing Xia; Patrick Concannon; David A Ostrov; Michael J Clare-Salzler
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

7.  Type III interferons are expressed by Coxsackievirus-infected human primary hepatocytes and regulate hepatocyte permissiveness to infection.

Authors:  K Lind; E Svedin; R Utorova; V M Stone; M Flodström-Tullberg
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

8.  The innate immune receptor MDA5 limits rotavirus infection but promotes cell death and pancreatic inflammation.

Authors:  Yu Dou; Howard Ch Yim; Carl D Kirkwood; Bryan Rg Williams; Anthony J Sadler
Journal:  EMBO J       Date:  2017-08-29       Impact factor: 11.598

Review 9.  Innate Immunity and Immune Evasion by Enterovirus 71.

Authors:  Prabuddha S Pathinayake; Alan C-Y Hsu; Peter A B Wark
Journal:  Viruses       Date:  2015-12-14       Impact factor: 5.048

10.  Infection- and procedure-dependent effects on pulmonary gene expression in the early phase of influenza A virus infection in mice.

Authors:  Matthias Preusse; Mohamed A Tantawy; Frank Klawonn; Klaus Schughart; Frank Pessler
Journal:  BMC Microbiol       Date:  2013-12-17       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.